FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine
FDA amended it’s Emergency Use Authorization to shorten Moderna’s vaccine booster dose interval from six to five months.
FDA announced on Jan 7, 2022, that it had amended it’s Emergency Use Authorization for the Moderna COVID-19 vaccine to shorten the time between the completion of the two-dose primary vaccination series and the booster dose. For individuals aged 18 years or older, the time has been reduced from six months to five months.
"The country is in the middle of a wave of the highly contagious omicron variant, which spreads more rapidly than the original SARS-CoV-2 virus and other variants that have emerged," said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, in the agency’s press release. "Vaccination is our best defense against COVID-19, including the circulating variants, and shortening the length of time between completion of a primary series and a booster dose may help reduce waning immunity. Today's action also brings consistency in the timing for administration of a booster dose among the available mRNA vaccines. We encourage everyone to get vaccinated—it's never too late to get your COVID-19 vaccine or booster."
Common side effects reported by individuals who received a booster dose of the Moderna COVID-19 vaccine include pain, redness and swelling at the injection site, fatigue, headache, muscle or joint pain, and chills. Additional side effects, as well as the risks of myocarditis and pericarditis, can be found on fact sheets provided by FDA.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
